SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Magellan Health, Inc. (NASDAQ: MGLN) today announced financial results for the fourth quarter and full year ended December 31, 2018, as summarized below:
| Three Months Ended | Years Ended | |||||||||||||||||||||||||
| December 31 | December 31 | |||||||||||||||||||||||||
| (In millions, except per share results) | ||||||||||||||||||||||||||
|
2018 |
2017 |
Chg |
2018 |
2017 |
Chg |
|||||||||||||||||||||
| Net revenue | $ | 1,844.6 | $ | 1,694.4 | 8.9 | % | $ | 7,314.2 | $ | 5,838.6 | 25.3 | % | ||||||||||||||
| Net income (loss) | $ | (28.0 | ) | $ | 54.5 | -151.3 | % | $ | 24.2 | $ | 110.2 | -78.1 | % | |||||||||||||
| Segment profit [1] | $ | 16.0 | $ | 99.0 | -83.8 | % | $ | 228.0 | $ | 310.9 | -26.7 | % | ||||||||||||||
| Adjusted net income (loss) [1] | $ | (18.6 | ) | $ | 64.2 | -128.9 | % | $ | 61.7 | $ | 144.8 | -57.4 | % | |||||||||||||
| Per share results: | ||||||||||||||||||||||||||
| Earnings (Loss) per share | $ | (1.16 | ) | $ | 2.17 | -153.5 | % | $ | 0.97 | $ | 4.51 | -78.5 | % | |||||||||||||
| Adjusted earnings (loss) per share [1] | $ | (0.77 | ) | $ | 2.55 | -130.2 | % | $ | 2.46 | $ | 5.92 | -58.4 | % | |||||||||||||
| [1] Refer to the Basis of Presentation for a discussion of non-GAAP financial measures. | ||||||||||||||||||||||||||
Highlights Include:
- Net revenue for the year ended December 31, 2018 increased to $7.3 billion from 2017.
- Net income for the year ended December 31, 2018 decreased to $24.2 million from 2017.
- Segment profit for the year ended December 31, 2018 decreased to $228.0 million from 2017.
- Adjusted net income for the year ended December 31, 2018 decreased to $61.7 million from 2017.
- Unrestricted cash and investments were $130.4 million as of December 31, 2018. Approximately $63.3 million of the unrestricted cash and investments at December 31, 2018 is related to excess capital and undistributed earnings held at regulated entities.
- The Company is confirming its full year 2019 earnings guidance.
“Relative to our previous expectations, the fourth quarter was negatively impacted by approximately $50 million of both out-of-period and non-recurring items, primarily related to retrospective rate adjustments in New York which occurred subsequent to our guidance call in December. We do not expect these items to have a material impact on 2019 earnings and are therefore confirming 2019 guidance,” said Jonathan N. Rubin, chief financial officer of Magellan Health.
Barry M. Smith, chairman and chief executive officer of Magellan Health, said, “While 2018 was challenging, we are only mid-way through our work to create a stronger, more sustainable foundation for the Company. For decades, Magellan was the leader in the carve-out specialty and behavioral health space. While these capabilities remain valuable and relevant today, the reality is that the market has changed to a much more integrated model. We recognized this and proactively took steps to transform our business in a significant way. We have made solid progress in shifting our revenue stream into growth markets over the last five years.”
Mr. Smith continued, “Looking to the future, we are confident that we can address our operational issues and deliver profitable growth and value creation. We are implementing a multi-year margin improvement plan to increase adjusted net income margin to over 2 percent.”
Net Revenue
For the full year ended December 31, 2018, net revenue increased 25.3 percent to $7.3 billion from $5.8 billion for the year ended December 31, 2017. This increase was mainly driven by the full year impact of the acquisition of Senior Whole Health (SWH) and the impact of net business growth.
Segment Profit
For the year ended December 31, 2018, segment profit decreased 26.7 percent to $228.0 million from $310.9 million for the year ended December 31, 2017.
- Healthcare segment profit for the full year ended December 31, 2018, was $149.1 million versus $202.7 million in 2017. This 2018 decrease was primarily driven by cost of care pressure in Magellan Complete Care of Virginia, rate reductions in Magellan Complete Care of Florida, and unfavorable rate adjustments in New York, partially offset by a full year contribution of Massachusetts from the Senior Whole Health acquisition. Results in the quarter were unfavorably impacted by significant out-of-period and non-recurring adjustments to revenue for our New York contract.
- We reported Pharmacy Management segment profit of $104.4 million for the year ended December 31, 2018, which was a decrease from the $139.9 million in 2017. The year-over-year decrease was primarily due to the loss of specialty carve-out business during the first half of 2018 as well as $7 million of unfavorable non-recurring items in the fourth quarter related to inventory, rebate receivables, and prior year customer settlements.
- Regarding other financial results, corporate costs inclusive of eliminations, but excluding stock compensation expense, totaled $25.6 million for the year ended December 31, 2018, compared to $31.8 million in 2017. The decrease is mainly due to a lower discretionary benefits in 2018, higher corporate development costs in 2017 related to the SWH acquisition, and a litigation settlement recorded in 2017.
Cash Flow & Balance Sheet
Cash flow from operations for the year ended December 31, 2018, was $164.8 million, as compared to cash flow from operations of $162.3 million for the year ended December 31, 2017.
As of December 31, 2018, the Company’s unrestricted cash and investments totaled $130.4 million, which represents a decrease of $130.8 million from the balance at December 31, 2017, largely due to the pay down of debt and share repurchases. Approximately $63.3 million of the unrestricted cash and investments at December 31, 2018 is related to excess capital and undistributed earnings held at regulated entities.
Restricted cash and investments at December 31, 2018, of $527.7 million reflect an increase of $62.3 million from the balance at December 31, 2017. This increase is primarily attributable to the growth in MCC Virginia.
As a result of the shortfall in earnings during 2018, we recently amended our 2017 Credit Agreement with our lenders to allow for a maximum net leverage up to 3.25 times trailing 12 month EBITDA until September 30, 2019, 2.75 times at December 31, 2019, and 2.5 times thereafter.
Outlook
The Company is confirming its 2019 full year earnings guidance ranges.
| 2019 Guidance | |||||||||
|
Low |
High |
||||||||
| Net revenue | $ |
7,200.0 |
$ | 7,500.0 | |||||
| Income before income taxes | $ | 75.0 | $ | 117.0 | |||||
| Net income | $ | 52.0 | $ | 79.0 | |||||
| Segment Profit[1] | $ | 270.0 | $ | 290.0 | |||||
| Adjusted net income[1] | $ | 90.0 | $ | 114.0 | |||||
| Per share results: | |||||||||
| Earnings per share[2] | $ | 2.14 | $ | 3.25 | |||||
| Adjusted earnings per share[1][2] | $ | 3.70 | $ | 4.69 | |||||
| [1] | Refer to the Basis of Presentation for a discussion of non-GAAP financial measures. | |
| [2] | 2019 EPS and Adjusted EPS guidance includes share repurchases and option exercises through the close of business February 22, 2019, but excludes the impact of any potential future activity. | |
Earnings Conference Call
Management will discuss the Company’s fourth quarter results on a conference call scheduled for Thursday, February 28, 2019 at 8:30 a.m. Eastern. To participate in the conference call, dial 1-800-857-1812 and use passcode “4th Quarter 2018 Earnings Call” approximately 10 minutes before the start of the call. The conference call will also be available live via webcast at Magellan's investor relations page at MagellanHealth.com. A telephonic replay will be available shortly after the conclusion of the call through March 28, 2019. This replay may be accessed by dialing 1-866-435-5412 (Domestic) or 1-203-369-1031 (International). A replay of the webcast will also be available at the site listed above for 30 days, beginning approximately two hours after its conclusion.
Basis of Presentation
In addition to results determined under Generally Accepted Accounting Principles (GAAP), Magellan provides certain non-GAAP financial measures that management believes are useful in assessing the Company’s performance. Following is a description of these important non-GAAP measures.
Segment profit is equal to net revenue less the sum of cost of care, cost of goods sold, direct service costs and other operating expenses, and includes income from unconsolidated subsidiaries, but excludes segment profit or loss from non-controlling interests held by other parties, stock compensation expense, special charges or benefits, as well as changes in the fair value of contingent consideration recorded in relation to acquisitions.
Adjusted net income and adjusted earnings per share reflect certain adjustments made for acquisitions completed after January 1, 2013, to exclude non-cash stock compensation expense resulting from restricted stock purchases by sellers, changes in the fair value of contingent consideration, amortization of identified acquisition intangibles, as well as impairment of identified acquisition intangibles.
Included in the tables issued with this press release are the reconciliations from GAAP measures to the corresponding non-GAAP measures.
About Magellan Health: Magellan Health, Inc., a Fortune 500 company, is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. For more information, visit MagellanHealth.com.
Forward-Looking Statements
This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the Securities and Exchange Commission’s Fair Disclosure Regulation. This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties, many of which are out of our control. All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding 2019 guidance for net revenue, income before income taxes, net income, earnings per share, segment profit, adjusted net income, adjusted earnings per share; and multi-year margin improvement plan, growth opportunities, business environment, long term opportunities and strategy. These statements are based on management’s analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the Company’s customers to manage the healthcare services of their members directly; changes in rates paid to and/or by the Company by customers and/or providers; higher utilization of healthcare services by the Company’s risk members; delays, higher costs or inability to implement new business or other Company initiatives; the impact of changes in the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; healthcare reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, to be filed with the Securities and Exchange Commission later today, and the Company’s subsequent Quarterly Reports on Form 10-Q to be filed during 2019. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit, adjusted net income, and adjusted EPS information referred to herein may be considered a non-GAAP financial measure. Further information regarding these measures, including the reasons management considers this information useful to investors, are included in the Company’s most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | ||||||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||||||
| (In thousands) | ||||||||||||
| December 31, 2017 | December 31, 2018 | |||||||||||
| ASSETS | ||||||||||||
| Current Assets: | ||||||||||||
| Cash and cash equivalents | $ | 398,732 | $ | 272,308 | ||||||||
| Accounts receivable, net | 660,775 | 756,059 | ||||||||||
| Short-term investments | 310,578 | 382,582 | ||||||||||
| Pharmaceutical inventory | 40,945 | 40,818 | ||||||||||
| Other current assets | 72,323 | 95,400 | ||||||||||
| Total Current Assets | 1,483,353 | 1,547,167 | ||||||||||
| Property and equipment, net | 158,638 | 150,748 | ||||||||||
| Long-term investments | 17,287 | 3,161 | ||||||||||
| Deferred income taxes | 813 | 3,411 | ||||||||||
| Other long-term assets | 22,567 | 24,530 | ||||||||||
| Goodwill | 1,006,288 | 1,018,156 | ||||||||||
| Other intangible assets, net | 268,288 | 231,883 | ||||||||||
| Total Assets | $ | 2,957,234 | $ | 2,979,056 | ||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||
| Current Liabilities: | ||||||||||||
| Accounts payable | $ | 74,300 | $ | 72,077 | ||||||||
| Accrued liabilities | 193,635 | 231,356 | ||||||||||
| Short-term contingent consideration | 6,892 | 8,000 | ||||||||||
| Medical claims payable | 327,625 | 393,547 | ||||||||||
| Other medical liabilities | 177,002 | 169,639 | ||||||||||
| Current debt, capital lease and deferred financing obligations | 112,849 | 24,274 | ||||||||||
| Total Current Liabilities | 892,303 | 898,893 | ||||||||||
| Long-term debt, capital lease and deferred financing obligations | 740,888 | 728,608 | ||||||||||
| Deferred income taxes | 12,298 | 11,167 | ||||||||||
| Tax contingencies | 14,226 | 16,478 | ||||||||||
| Long-term contingent consideration | 1,925 | 2,124 | ||||||||||
| Deferred credits and other long-term liabilities | 19,100 | 36,483 | ||||||||||
| Total Liabilities | 1,680,740 | 1,693,753 | ||||||||||
| Stockholders’ Equity: | ||||||||||||
| Ordinary common stock | 530 | 535 | ||||||||||
| Additional paid-in capital | 1,274,811 | 1,326,645 | ||||||||||
| Retained earnings | 1,399,495 | 1,419,449 | ||||||||||
| Accumulated other comprehensive loss | (380 | ) | (324 | ) | ||||||||
| Ordinary common stock in treasury, at cost | (1,397,962 | ) | (1,461,002 | ) | ||||||||
| Total Stockholders’ Equity | 1,276,494 | 1,285,303 | ||||||||||
| Total Liabilities and Stockholders’ Equity | $ | 2,957,234 | $ | 2,979,056 | ||||||||
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||||||||||||||||
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | |||||||||||||||||||||
| (In thousands, except per share amounts) | |||||||||||||||||||||
| Three Months Ended | Years Ended | ||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||
| 2017 | 2018 | 2017 | 2018 | ||||||||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||||||||
| Net revenue: | |||||||||||||||||||||
| Managed care and other | $ | 1,093,785 | $ | 1,207,552 | $ | 3,479,182 | $ | 4,878,442 | |||||||||||||
| PBM | 600,630 | 637,093 | 2,359,401 | 2,435,709 | |||||||||||||||||
| Total net revenue | 1,694,415 | 1,844,645 | 5,838,583 | 7,314,151 | |||||||||||||||||
| Costs and expenses: | |||||||||||||||||||||
| Cost of care | 779,146 | 959,906 | 2,413,770 | 3,762,412 | |||||||||||||||||
| Cost of goods sold | 563,240 | 593,793 | 2,211,910 | 2,283,022 | |||||||||||||||||
| Direct service costs and other operating expenses (1)(2) | 261,653 | 277,835 | 941,883 | 1,071,535 | |||||||||||||||||
| Depreciation and amortization | 32,810 | 35,358 | 115,706 | 132,660 | |||||||||||||||||
| Interest expense | 9,266 | 9,362 | 25,977 | 35,396 | |||||||||||||||||
| Interest and other income | (2,086 | ) | (4,090 | ) | (5,887 | ) | (14,068 | ) | |||||||||||||
| Total costs and expenses | 1,644,029 | 1,872,164 | 5,703,359 | 7,270,957 | |||||||||||||||||
| Income (loss) before income taxes | 50,386 | (27,519 | ) | 135,224 | 43,194 | ||||||||||||||||
| Provision (benefit) for income taxes | (4,123 | ) | 448 | 25,083 | 19,013 | ||||||||||||||||
| Net income (loss) | 54,509 | (27,967 | ) | 110,141 | 24,181 | ||||||||||||||||
| Less: net loss attributable to non-controlling interest | - | - | (66 | ) | - | ||||||||||||||||
| Net income (loss) attributable to Magellan | $ | 54,509 | $ | (27,967 | ) | $ | 110,207 | $ | 24,181 | ||||||||||||
| Weighted average number of common shares outstanding — basic | 23,921 | 24,048 | 23,333 | 24,349 | |||||||||||||||||
| Weighted average number of common shares outstanding — diluted | 25,113 | 24,048 | 24,440 | 25,035 | |||||||||||||||||
| Net income (loss) attributable to Magellan per common share — basic | $ | 2.28 | $ | (1.16 | ) | $ | 4.72 | $ | 0.99 | ||||||||||||
| Net income (loss) attributable to Magellan per common share — diluted | $ | 2.17 | $ | (1.16 | ) | $ | 4.51 | $ | 0.97 | ||||||||||||
| Net income (loss) | $ | 54,509 | $ | (27,967 | ) | $ | 110,141 | $ | 24,181 | ||||||||||||
| Other comprehensive income (loss): | |||||||||||||||||||||
| Unrealized gain (loss) on available-for-sale securities (3) | (232 | ) | 48 | (205 | ) | 56 | |||||||||||||||
| Comprehensive income (loss) | 54,277 | (27,919 | ) | 109,936 | 24,237 | ||||||||||||||||
| Less: comprehensive income (loss) attributable to non-controlling interest | - | - | (66 | ) | - | ||||||||||||||||
| Comprehensive income (loss) attributable to Magellan | $ | 54,277 | $ | (27,919 | ) | $ | 110,002 | $ | 24,237 | ||||||||||||
| (1) Includes stock compensation expense of $7,282 and $2,067 for the three months ended December 31, 2017 and 2018, respectively, and $39,116 and $29,472 for the twelve months ended December 31, 2017 and 2018, respectively. | |
| (2) Includes changes in fair value of contingent consideration of $1,327 and $856 for the three months ended December 31, 2017 and 2018, respectively, and $696 and $1,307 for the twelve months ended December 31, 2017 and 2018, respectively. | |
| (3) Net of income tax provision of ($26) and $15 for the three months ended December 31, 2017 and 2018, respectively, and ($8) and $18 for the twelve months ended December 31, 2017 and 2018, respectively. | |
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||
| (In thousands) | |||||||||||
| Years Ended | |||||||||||
| December 31, | |||||||||||
| 2017 | 2018 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net income | $ | 110,141 | $ | 24,181 | |||||||
| Adjustments to reconcile net income to net cash from operating activities: | |||||||||||
| Depreciation and amortization | 115,706 | 132,660 | |||||||||
| Non-cash interest expense | 4,757 | 1,221 | |||||||||
| Non-cash stock compensation expense | 39,116 | 29,472 | |||||||||
| Non-cash income tax benefit | (30,981 | ) | (1,725 | ) | |||||||
| Non-cash amortization on investments | 3,924 | 1,344 | |||||||||
| Changes in assets and liabilities, net of effects from acquisitions of businesses: | |||||||||||
| Accounts receivable, net | (40,910 | ) | (99,295 | ) | |||||||
| Pharmaceutical inventory | 17,605 | 127 | |||||||||
| Other assets | (4,565 | ) | (25,774 | ) | |||||||
| Accounts payable and accrued liabilities | (84,445 | ) | 9,139 | ||||||||
| Medical claims payable and other medical liabilities | 26,235 | 72,347 | |||||||||
| Contingent consideration | 696 | 1,307 | |||||||||
| Tax contingencies | 1,681 | 1,803 | |||||||||
| Deferred credits and other long-term liabilities | 3,218 | 18,020 | |||||||||
| Other | 95 | 17 | |||||||||
| Net cash provided by operating activities | 162,273 | 164,844 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Capital expenditures | (57,232 | ) | (68,275 | ) | |||||||
| Acquisitions and investments in businesses, net of cash acquired | (232,403 | ) | (958 | ) | |||||||
| Purchases of investments | (449,873 | ) | (557,232 | ) | |||||||
| Proceeds from maturities and sales of investments | 423,118 | 498,032 | |||||||||
| Net cash used in investing activities | (316,390 | ) | (128,433 | ) | |||||||
| Cash flows from financing activities: | |||||||||||
| Proceeds from issuance of debt | 1,041,736 | - | |||||||||
| Payments to acquire treasury stock | (21,765 | ) | (62,640 | ) | |||||||
| Proceeds from exercise of stock options | 44,355 | 23,064 | |||||||||
| Payments on debt, capital lease and deferred financing obligations | (803,393 | ) | (122,239 | ) | |||||||
| Payments on contingent consideration | (3,032 | ) | - | ||||||||
| Other | (9,560 | ) | (1,020 | ) | |||||||
| Net cash provided by (used in) financing activities | 248,341 | (162,835 | ) | ||||||||
| Net increase (decrease) in cash and cash equivalents | 94,224 | (126,424 | ) | ||||||||
| Cash and cash equivalents at beginning of period | 304,508 | 398,732 | |||||||||
| Cash and cash equivalents at end of period | $ | 398,732 | $ | 272,308 | |||||||
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||||||||||||||||
| CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT | |||||||||||||||||||||
| (In thousands) | |||||||||||||||||||||
| Three Months Ended | Years Ended | ||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||
| 2017 | 2018 | 2017 | 2018 | ||||||||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||||||||
|
Healthcare |
|||||||||||||||||||||
| Managed care and other revenue | $ | 1,016,180 | $ | 1,149,694 | $ | 3,206,277 | $ | 4,638,622 | |||||||||||||
| Cost of care | (779,146 | ) | (959,906 | ) | (2,413,770 | ) | (3,762,412 | ) | |||||||||||||
| Direct service costs and other | (172,769 | ) | (192,108 | ) | (601,201 | ) | (735,366 | ) | |||||||||||||
| Stock compensation expense (1) | 2,301 | (875 | ) | 10,689 | 6,982 | ||||||||||||||||
| Changes in fair value of contingent consideration (1) | 1,327 | 856 | 696 | 1,307 | |||||||||||||||||
| Less: non-controlling interest loss (2) | - | - | (56 | ) | - | ||||||||||||||||
| Healthcare segment profit | 67,893 | (2,339 | ) | 202,747 | 149,133 | ||||||||||||||||
|
Pharmacy Management |
|||||||||||||||||||||
| Managed care and other revenue | 77,519 | 58,017 | 273,489 | 240,427 | |||||||||||||||||
| PBM revenue | 634,188 | 684,691 | 2,491,044 | 2,625,417 | |||||||||||||||||
| Cost of goods sold | (599,369 | ) | (640,843 | ) | (2,341,979 | ) | (2,468,170 | ) | |||||||||||||
| Direct service costs and other | (76,743 | ) | (77,695 | ) | (302,525 | ) | (298,713 | ) | |||||||||||||
| Stock compensation expense (1) | 2,787 | 1,206 | 19,881 | 5,458 | |||||||||||||||||
| Pharmacy Management segment profit | 38,382 | 25,376 | 139,910 | 104,419 | |||||||||||||||||
|
Corporate and Elimination (3) |
|||||||||||||||||||||
| Managed care and other revenue | 86 | (159 | ) | (584 | ) | (607 | ) | ||||||||||||||
| PBM revenue | (33,558 | ) | (47,598 | ) | (131,643 | ) | (189,708 | ) | |||||||||||||
| Cost of goods sold | 36,129 | 47,050 | 130,069 | 185,148 | |||||||||||||||||
| Direct service costs and other | (12,141 | ) | (8,032 | ) | (38,157 | ) | (37,456 | ) | |||||||||||||
| Stock compensation expense (1) | 2,194 | 1,736 | 8,546 | 17,032 | |||||||||||||||||
| Less: non-controlling interest loss (2) | - | - | (3 | ) | - | ||||||||||||||||
| Corporate and Elimination | (7,290 | ) | (7,003 | ) | (31,766 | ) | (25,591 | ) | |||||||||||||
|
Consolidated |
|||||||||||||||||||||
| Managed care and other revenue | 1,093,785 | 1,207,552 | 3,479,182 | 4,878,442 | |||||||||||||||||
| PBM revenue | 600,630 | 637,093 | 2,359,401 | 2,435,709 | |||||||||||||||||
| Cost of care | (779,146 | ) | (959,906 | ) | (2,413,770 | ) | (3,762,412 | ) | |||||||||||||
| Cost of goods sold | (563,240 | ) | (593,793 | ) | (2,211,910 | ) | (2,283,022 | ) | |||||||||||||
| Direct service costs and other | (261,653 | ) | (277,835 | ) | (941,883 | ) | (1,071,535 | ) | |||||||||||||
| Stock compensation expense (1) | 7,282 | 2,067 | 39,116 | 29,472 | |||||||||||||||||
| Changes in fair value of contingent consideration (1) | 1,327 | 856 | 696 | 1,307 | |||||||||||||||||
| Less: non-controlling interest loss (2) | - | - | (59 | ) | - | ||||||||||||||||
| Consolidated segment profit | $ | 98,985 | $ | 16,034 | $ | 310,891 | $ | 227,961 | |||||||||||||
| Reconciliation of income before income taxes to segment profit: | |||||||||||||||||||||
| Income (loss) before income taxes | $ | 50,386 | $ | (27,519 | ) | $ | 135,224 | $ | 43,194 | ||||||||||||
| Stock compensation expense | 7,282 | 2,067 | 39,116 | 29,472 | |||||||||||||||||
| Changes in fair value of contingent consideration | 1,327 | 856 | 696 | 1,307 | |||||||||||||||||
| Non-controlling interest segment (profit) loss | - | - | 59 | - | |||||||||||||||||
| Depreciation and amortization | 32,810 | 35,358 | 115,706 | 132,660 | |||||||||||||||||
| Interest expense | 9,266 | 9,362 | 25,977 | 35,396 | |||||||||||||||||
| Interest and other income | (2,086 | ) | (4,090 | ) | (5,887 | ) | (14,068 | ) | |||||||||||||
| Segment profit | $ | 98,985 | $ | 16,034 | $ | 310,891 | $ | 227,961 | |||||||||||||
| (1) Stock compensation expense, changes in the fair value of contingent consideration recorded in relation to acquisitions and impairment of intangible assets are included in direct service costs and other operating expenses; however, these amounts are excluded from the computation of segment profit. | |
| (2) The non-controlling portion of AlphaCare's segment loss is excluded from the computation of segment profit. | |
| (3) Healthcare subcontracts with Pharmacy Management to provide pharmacy benefits management services for certain of Healthcare’s customers. In addition, Pharmacy Management provides pharmacy benefits management for the Company’s employees covered under its medical plan. As such, revenue, cost of goods sold and direct service costs and other related to these arrangements are eliminated. | |
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||||||||||||||||
| NON-GAAP MEASURES | |||||||||||||||||||||
| (In thousands, except per share amounts) | |||||||||||||||||||||
| Three Months Ended | Years Ended | ||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||
| 2017 | 2018 | 2017 | 2018 | ||||||||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||||||||
| Net income (loss) attributable to Magellan | $ | 54,509 | $ | (27,967 | ) | $ | 110,207 | $ | 24,181 | ||||||||||||
| Adjusted for acquisitions starting in 2013 | |||||||||||||||||||||
| Stock compensation expense | 1,497 | - | 16,215 | 530 | |||||||||||||||||
| Changes in fair value of contingent consideration | 1,327 | 856 | 696 | 1,307 | |||||||||||||||||
| Amortization of acquired intangibles | 12,076 | 12,402 | 37,265 | 49,078 | |||||||||||||||||
| Tax impact | (5,186 | ) | (3,858 | ) | (19,558 | ) | (13,435 | ) | |||||||||||||
| Adjusted net income (loss) | $ | 64,223 | $ | (18,567 | ) | $ | 144,825 | $ | 61,661 | ||||||||||||
| Net income (loss) per common share attributable to Magellan —diluted | $ | 2.17 | $ | (1.16 | ) | $ | 4.51 | $ | 0.97 | ||||||||||||
| Adjusted for acquisitions starting in 2013 | |||||||||||||||||||||
| Stock compensation expense | 0.05 | - | 0.66 | 0.02 | |||||||||||||||||
| Changes in fair value of contingent consideration | 0.06 | 0.03 | 0.03 | 0.05 | |||||||||||||||||
| Amortization of acquired intangibles | 0.48 | 0.52 | 1.52 | 1.96 | |||||||||||||||||
| Tax impact | (0.21 | ) | (0.16 | ) | (0.80 | ) | (0.54 | ) | |||||||||||||
| Adjusted earnings (loss) per share | $ | 2.55 | $ | (0.77 | ) | $ | 5.92 | $ | 2.46 | ||||||||||||
(MGLN-GEN)
